^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CPX-351 IN THERAPHY RELATED ACUTE MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES: A MULTICENTER REAL-LIFE EXPERIENCE IN YOUNG PATIENTS (<60 YEARS OLD)
Published date:
05/12/2021
Excerpt:
One patient showed a partial remission (PR)....The patient in PR, who was FLT3 mutated, underwent reinduction, with administration of CPX-351 in day 1 and 3, obtaining a CR….We found that CPX-351 is active in young patients with t-AML and AML-MRC with a rate of ORR higher than that reported in the pivotal study (63% vs 47%).
